Associate Professor Katherine Andrews from Griffith’s Eskitis Institute for Drug Discovery has joined an international team of researchers working on new drugs to combat deadly parasites.
Dr Mel Spigelman, President and CEO of the Global Alliance for TB Drug Development, has delivered a lecture to mark the 10th Anniversary of the Eskitis Institute.
Professor Katherine Andrews, Director of the Griffith Institute for Drug Discovery (GRIDD), has been recognised as a Fellow of the Australian Society for Parasitology for her work on malaria drug discovery.
Can slight variations in lab environments affect the malaria-causing parasite (Plasmodium) and its tolerance to anti-malarial drugs? Griffith University’s Sandra Duffy believes it’s possible.
Griffith University scientists have helped discover new compounds which could help block the transmission of the deadly disease malaria. A team of Griffith researchers has found a novel class of compounds, the hexahydro quinoline (HHQ), with potent activity against the parasite stages responsible for the clinical symptoms of malaria and its transmission to mosquitoes.
Professor Vicky Avery, from Griffith's Eskitis Institute, is part of an international discovery which could lead to powerful new anti-malaria drugs
Medicines for Malaria Venture (MMV) estimates billions of people, especially children and pregnant women, are at risk of malaria in...
